Timely selec­tion of the most effec­tive ther­apy saves treat­ment costs, pro­longs life­time of the patient, and improves his/her qual­ity of life !



The Prognosis, Prediction and Monitoring Tests are based on the mol­e­c­u­lar detec­tion of Cir­cu­lat­ing Tumor Cells (CTCs) as a mea­sure of ther­apy effi­cacy and recur­rence of can­cer. The pres­ence and molecular char­ac­ter­is­tics of CTCs are ana­lyzed by quan­tifi­ca­tion of RNA pan­els spe­cific for each type of cancer.


Our CTC tests pro­vide reli­able information

   »   to stop inef­fec­tive treat­ment early on, avoid­ing unnec­es­sary side effects which are a heavy bur­den for the patient;

   »  to choose an alter­na­tive, more effec­tive therapy;

   »  to detect can­cer relapse ear­lier than any other cur­rently avail­able method, enabling ear­li­est pos­si­ble onset of treatment.


All Prognosis, Prediction and Monitoring Tests are non-​invasive and rely on novel con­cepts ensur­ing unprece­dented sen­si­tiv­i­tiy and speci­ficity. This has already been demon­strated for ovar­ian cancer. These tests will be pro­vided for ovar­ian can­cer, breast can­cer, endome­trial can­cer, cer­vi­cal can­cer, col­orec­tal can­cer, and lung cancer.


© OncoLab Diagnostics GmbH 2019

OncoLab Diagnostics GmbH
TFZ - Viktor Kaplan-Strasse 2, Objekt E
2700 Wiener Neustadt / Lower Austria